Study of ORL-1F (L-fucose) in Patients With Leukocyte Adhesion Deficiency Type II

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03354533

Enrollment

Registered

2017-11-28

Start date

2012-01-01

Completion date

2018-11-01

Last updated

2019-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukocyte Adhesion Deficiency, Type II

Brief summary

Study of ORL-1F in Patients With Leukocyte Adhesion Deficiency Type II

Interventions

DRUGL-fucose

Oral ORL-1F

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of Leukocyte Adhesion Deficiency Type II. * Less than 18 years old.

Exclusion criteria

* Diagnosis of any other disease that is not a manifestation of Leukocyte Adhesion Deficiency Type II.

Design outcomes

Primary

Measure	Time frame	Description
Decrease in infection frequency	12 months after treatment started	Statistically significant decrease in infection frequency

Secondary

Measure	Time frame	Description
Decrease in neutrophil count	30 days after treatment started	Statistically significant decrease in absolute neutrophil count

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026